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Abstract
Purpose—A key research objective in radiation oncology is to identify agents that can improve
chemoradiation therapy. Nanoparticle (NP) chemotherapeutics possess several properties, such as
preferential accumulation in tumors, that are uniquely suited for chemoradiation therapy. To
facilitate the clinical translation of NP chemotherapeutics in chemoradiation therapy, we
conducted preclinical evaluation of Genexol-PM, the only clinically approved NP
chemotherapeutic with a controlled drug release profile, as a radiosensitizer using non-small cell
lung cancer (NSCLC) as a model disease.
Methods and Materials—The physical characteristics and drug release profile of Genexol-PM
were characterized. Genexol-PM’s efficacy as a radiosensitizer was evaluated in vitro using
NSCLC cell lines and in vivo using mouse xenograft models of NSCLC. Paclitaxel dose to normal
lung and liver after Genexol-PM administration were quantified and compared with that after
Taxol administration.
Results—Genexol-PM has a size of 23.91 ± 0.41 nm and surface charge of −8.1 ± 3.1 mV. It
releases paclitaxel in a controlled release profile. In vitro evaluation of Genexol-PM as a
radiosensitizer showed it is an effective radiosensitizer and is more effective than Taxol, its small
molecule counterpart, at the half maximal inhibitory concentration. In vivo study of Genexol-PM
as a radiosensitizer demonstrated that it is more effective as a radiosensitizer than Taxol. We also
found that Genexol-PM leads to lower paclitaxel exposure to normal lung tissue than Taxol at 6
hours postad-ministration.
Conclusions—We have demonstrated that Genexol-PM is more effective than Taxol as a
radiosensitizer in the preclinical setting and holds high potential for clinical translation. Our data
support the clinical evaluation of Genexol-PM in chemoradiation therapy for NSCLC.
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The concurrent administration of chemotherapy and radiation therapy, also called
chemoradiation therapy, is an important treatment paradigm in the curative management of
many cancers (1). Chemoradiation therapy has not only consistently shown improved local
tumor control but also improves survival when compared with either sequential treatment or
sole administration of chemotherapy or radiation therapy in some malignancies (1, 2).
However, chemoradiation therapy is not without limitations. The concurrent use of both
chemotherapy and radiation therapy has significantly higher toxicities compared with either
treatment alone or sequential use (3). Thus, the development of agents and approaches to
further improve the therapeutic index of chemoradiation therapy has been a major research
objective. A key challenge in this effort has been to selectively deliver chemotherapeutics to
tumors while minimizing drug dose to normal tissue. Although traditional drug delivery
techniques have failed to address this challenge (4), the development of nanoparticle (NP)
formulations of chemotherapeutics offers an unprecedented opportunity. NP therapeutics
possess important characteristics that are uniquely suited for chemoradiotherapy. NPs, as
macromolecules, preferentially accumulate in tumors through the enhanced permeability and
retention (EPR) effect, leading to high intratumoral drug concentrations (5). NPs are also
unable to penetrate normal vasculatures and capillaries, thus leading to lower drug doses to
normal tissues compared with their small molecule counterparts. Moreover, NP therapeutics
have been found to have lower systemic toxicity than small molecules (6). Lastly, NP
formulations of chemotherapeutics can release their cargo in a controlled fashion (5). Such
prolonged release can increase the synergistic effects of chemotherapy and radiation
therapy. Indeed, several preclinical studies have demonstrated that NP chemotherapeutics
can improve the therapeutic efficacy of chemoradiotherapy (7, 8). However, there have been
no reports evaluating NP therapeutics that are clinically approved or under-going clinical
investigation for use in chemoradiation therapy. Such studies are necessary for clinical
translation of NP therapeutics in chemoradiation therapy. To fill this knowledge gap, we
conducted a preclinical evaluation of Genexol-PM, the only clinically approved second-
generation NP chemotherapeutic with a controlled drug release profile, in chemoradiation
therapy using non-small cell lung cancer (NSCLC) as a model disease.
Genexol-PM is a polymeric NP micelle formulation of paclitaxel that has been approved in
South Korea for the treatment of breast cancer and NSCLC (9, 10). It is composed of low-
molecular-weight amphiphilic diblock copolymer, monomethoxy poly (ethylene glycol)-
block-poly(D,L-lactide) (mPEG-PDLLA) and paclitaxel (11). Genexol-PM has shown lower
toxicity than Taxol with its maximum tolerated dose identified as 2 to 3 times that of Taxol
(9-11). Given that chemoradiation therapy is often used for locally advanced and
unresectable NSCLC and paclitaxel has been shown be an excellent radiosensitizer in
NSCLC, we chose to study Genexol-PM in chemoradiation therapy using NSCLC as a
model disease. Moreover, chemoradiation therapy for NSCLC has significant toxicities with
approximately 5% to 10% of patients dying from treatment-related pulmonary toxicities (3,
12). Thus, there is a strong clinical need to improve chemoradiation therapy for NSCLC. In
this study, Genexol-PM was compared with Taxol in chemoradiation therapy in vitro using
NSCLC cell lines and in vivo using mouse flank xenograft models of NSCLC. We also




Genexol-PM was provided by Samyang Biopharmaceuticals Corporation (Seoul, Korea) as a
gift. Each gram of Genexol-PM contains 115 mg of paclitaxel. Genexol-PM was
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resuspended in phosphate buffer saline based on clinical administration protocol before use.
Taxol 6 mg/mL injectable solution (Teva, Sellersville, PA) was purchased from the
University of North Carolina Hospital pharmacy.
Characterization of Genexol-PM
Genexol-PM size (diameter, nm) and surface charge (ξ-potential, mV) were characterized
using a ZetaPALS dynamic light scattering detector (Brookhaven Instruments, Holtsville,
NY). Transmission electron microscopy (TEM) images of Genexol-PM were obtained at the
University of North Carolina (UNC) Microscopy Services Laboratory Core Facility. NPs
were stained using a phosphotungstate stain before TEM imaging.
Paclitaxel release characterization
To measure the release profile of paclitaxel from Genexol-PM, 0.1 mL of Genexol-PM
solution at a concentration of 1 mg/mL was aliquot equally into Slide-A-Lyzer MINI
dialysis microtubes with a molecular weight cut-off of 10 kDa (Pierce, Rockford, IL) and
subjected to dialysis as described previously (7). Paclitaxel content was quantitatively
analyzed using an Agilent 1100 HPLC (Paolo Alto, CA) equipped with a C18 chromolith
flash column (Merck, Darmstadt, Germany). Paclitaxel absorbance was measured by a UV-
VIS detector at 227 nm and a retention time of 8.5 min in 0.25 mL/min gradient (from 0:100
to 100:0) of acetonitrile/water.
Cell culture
NSCLC cell lines were acquired from the Lineberger Comprehensive Cancer Center Tissue
Culture Facility. A549 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM)
(Gibco, Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Mediatech,
Manassas, VA) and penicillin/streptomycin (Mediatech). H460 was cultured in RPMI 1640
(Gibco) with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 1.5 g/L Na bicarbonate, 10
mM HEPES (4-(2-hydroxyethyl)-1-piper-azineethanesulfonic acid) buffer, 1 mM Na
pyruvate, penicillin/streptomycin (Mediatech), 4.5 g/L glucose.
In vitro x-ray irradiation
Radiation therapy was given using a Precision X-RAD 320 (Precision X-Ray, North
Branford, CT) operating at 320 kvp and 12.5 mA as described previously (7).
Clonogenic survival assay
Cells were seeded at densities ranging from 100 to 200,000 cells in 4 mL of culture medium
in 25-mL flasks 1 day before treatment. Cells were treated with IC50 doses of Taxol (1.77
ug/mL for A549 and 17.7 ug/mL for H460) or Genexol-PM (15 ug/mL for A549 and 150
ug/mL for H460) for 1 hour and washed 3 times with fresh media after incubation. Cells
were irradiated with 2 fractions of 0, 1, 2, or 3 Gy separated by 12 hours. Cells were
incubated and counted as described previously (7). Data were analyzed using Origin Pro 8.6
software. Polynomial curve fitting was performed using second polynomial order.
In vivo tumor assay
Tumors were established in the upper dorsal region of Nu/Nu mice by injecting 1 × 106 of
H460 or A549 cells in a 1:1 RPMI:Matrigel solution. Tumors were incubated for 10 days
(H460) or 14 days (A549) to reach approximate tumor volume of 100 mm3 before treatment.
Mice (7 per experimental group) were treated intravenously with Taxol (2.5 mg/kg) or
Genexol-PM (21.5 mg/kg) and subsequently irradiated 6 hours postinjection. The mice were
randomized into experimental groups before treatment. The dose rate at a source-subject
distance of 70 cm was 50 cGy/min. Mice were irradiated with 5 daily fractions of 3 Gy. The
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head and abdomen regions of mice were shielded using 0.5 cm of lead. Only the truncal
region containing tumor xenograft was irradiated. Tumor volumes were calculated by
measuring 2 perpendicular diameters with a caliper and using the formula of V = 0.5 × a ×
b2 where, a and b are the larger and smaller diameters, respectively. The tumors were
measured every 2 days, and the relative percent change in tumor volume was calculated
using the relation 100 * (Vi – Vo)/Vo, where Vi is the volume calculated and Vo is the initial
volume on day 1.
Tumor volume was measured every other day until the tumor reached 3 times the initial
volume or 2 cm in the maximum dimension, at which point the animal was euthanized. All
animal work was approved and monitored by the UNC Animal Care and Use Committee.
Statistical methods
We used response features analysis to analyze our serial measures of tumor growth (13).
This method allows for the comparison of individual growth delay profiles by using
summary measures. The particular summary measure used was the AUC (or area under the
curve), which was particularly appropriate for the growth-delay profiles we encountered.
The Wilcoxon 2-group method (using Van der Waerden normal scores) was used to test
whether there was a significant difference in AUCs between chemoradiation therapy with
Genexol-PM compared with chemoradiation therapy with Taxol. Statistical analyses were
performed using SAS statistical software, version 9.2, from the SAS Institute (Cary, NC).
Quantification of paclitaxel dose in tissue
Mice bearing H460 tumors (5 animals per group) were treated intravenously with equivalent
paclitaxel dose of Taxol (2.5 mg/kg) or Genexol-PM (21.5 mg/kg). Mice were euthanized
after 6 h or 24 h, and organs were collected and weighed. Organs were homogenized 4:1 (v/
w) in chloroform to extract paclitaxel. Homogenate was centrifuged, and the organic layer
was collected, evaporated, and reconstituted in 0.1% acetic acid in methanol for analysis via
liquid chromatography-mass spectrometry using an Applied Biosystems API 4000 triple
quadrupole mass spectrometer with an atmospheric pressure chemical ionization interface.
Results
Characterization of Genexol-PM
Genexol-PM’s physical properties were characterized as these properties have not been
described in previous publications. Genexol-PM has a size of 23.91 ± 0.41 nm by dynamic
light scattering. The NPs are also monodispersewith a polydispersity index of 0.08 ± 0.02.
The NP size and dispersity were confirmed by TEM (Fig. 1A). We found that Genexol-PM
has a surface charge of −8.1 ± 3.1 mV. We also studied the drug release profile of Genexol-
PM. Paclitaxel release from the Genexol-PM demonstrated first-order controlled release
kinetics with ~65% drug released at 24 hours and 95% drug release at 48 hours (Fig. 1B).
In vitro radiosensitization with Genexol-PM
The therapeutic efficacy of Genexol-PM as a radiosensitizer in vitro was evaluated in 2
commonly studied NSCLC cell lines H460 (large cell) and A549 (adenocarcinoma). To
determine the sensitivity of each cell line to Genexol-PM, a dose-response curve was
performed with no radiation therapy for each cell line (Fig. S1). Radio-sensitization
experiments were conducted using IC50 concentrations as well as equivalent paclitaxel
concentrations of Genexol-PM and Taxol. Clonogenic survival curves of cells after
combined Genexol-PM and fractionated radiation therapy were generated for each cell line.
They were compared to that of fractionated radiation therapy alone. We demonstrated that
despite the lack of EPR effect in vitro, Genexol-PM is an effective radiosensitizer and is
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more effective than Taxol in both cell lines at IC50 doses (Fig. 2). The sensitizer
enhancement ratio (SER) of Taxol at 10% survival in H460 cells is 1.03, whereas the SER
of Genexol-PM is 1.12. The SER is greater in A549 cells at 10%; with Taxol at 1.12 and
Genexol-PM at 1.23. Also, Genexol-PM was as effective a radiosensitizer as Taxol at
equivalent paclitaxel doses (Fig. S2). These results confirmed that Genexol-PM is an
effective radiosensitizer.
In vivo radiosensitization with Genexol-PM
To validate the in vitro result and to evaluate the efficacy of Genexol-PM as a
radiosensitizer in vivo, we used a murine flank xenograft model of NSCLC. Mice bearing
either H460 or A549 cell xenograft tumors were treated with Genexol-PM, Taxol, or saline
followed by radiation therapy. After treatment with 5 daily fractions of 3 Gy, the tumor
growth delay curves demonstrated that chemoradiation therapy with Genexol-PM leads to
significantly longer tumor growth delay compared with chemoradiotherapy with Taxol in
H460 cells (P=.008; Fig. 3A). Although the difference between the 2 treatments does not
appear as significant in A549 cells (P=.18; Fig. 3B), the impression remains that
chemoradiation therapy with Genexol-PM is more effective. Since tumors that were treated
with chemotherapy only (Genexol-PM or Taxol) did not show significant difference in
growth delay, the difference between Genexol-PM+XRT and Taxol+XRT is likely due to
more effective radiosensitization by Genexol-PM (Fig. S3). Our results showed the high
potential of Genexol-PM in improving chemoradiation therapy.
Evaluation of normal tissue drug exposure
Pulmonary toxicity is the main cause of mortality and morbidity from chemoradiation
therapy for NSCLC. It is caused by normal lung tissue receiving both chemotherapy and
radiation therapy. To determine whether Genexol-PM can lead to lower normal lung
paclitaxel exposure, we compared the paclitaxel concentrations in mouse lungs after
Genexol-PM and Taxol administration. We found that Genexol-PM leads to significantly
lower lung paclitaxel concentration (P=.01) acutely after injection (6 hours). This difference
in drug concentration disappeared at 24 hours (Fig. 4). Given that NPs are generally cleared
through hepatic clearance and the concern over hepatotoxicity, we also compared the
paclitaxel concentration in mouse liver after Genexol-PM and Taxol administration.
Although not statistically significant, Genexol-PM lead to lower paclitaxel exposure to
mouse liver than paclitaxel at 6 hours (P=.30). Similar to the drug exposure in the lung, there
was no difference in liver paclitaxel concentration between Genexol-PM and Taxol at 24
hours.
Discussion
Advances in nanomedicine have enabled the development of many NP-based
chemotherapeutics (14). Although they have been widely used as chemotherapeutics, there
has been limited clinical evaluation of these drugs in chemoradiation therapy because of
toxicity concerns (15). Recent nanomedicine clinical translation efforts have focused on the
development of NP formulation of taxanes, a class of chemotherapeutics that is also used in
chemoradiation. Today, there are 2 clinically approved NP taxane formulations, nab-
paclitaxel (Abraxane) and Genexol-PM, with several additional therapeutics under clinical
investigation (paclitaxel poliglumex [Opaxio], BIND-014 [biologically targeted polymeric
NP docetaxel]) (5). Among these, Genexol-PM is the only NP therapeutic that possesses
controlled drug release and is approved for clinical use. Furthermore, the only other
approved NP taxane, nab-paclitaxel (nanoparticle albumin-bound paclitaxel), dissociates
upon administration and cannot take full advantage of the EPR effect (16). Therefore,
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Genexol-PM is the best NP therapeutic candidate for clinical translation in chemoradiation
therapy.
Preclinical studies have shown that the optimal NP physical characteristics for tumor
targeting are sizes <100 nm with negative surface charges (17). Genexol-PM’s properties
(23.0 ± 4.5 nm and −8.1 ± 3.1 mV) suggest that it is excellent for tumor targeting. Another
advantage of using Genexol-PM in chemoradiotherapy is its controlled drug release.
Although previous clinical investigations have demonstrated that prolonged drug exposure
can increase the therapeutic efficacy of chemoradiation therapy (18), most small molecule
chemotherapeutics, including taxanes, are too toxic to be administered continuously. NP
therapeutics, conversely, can increase drug exposure time in tumors without increasing
toxicity, both to local healthy tissue and systemically. In this study, we found Genexol-PM
releases paclitaxel in a controlled and slow fashion, with only 40% drug release after 16
hours and >90% of drug release after 48 hours. Such slow drug release should lead to
increased synergistic effects between paclitaxel and radiation therapy, which in turn should
result in improved therapeutic efficacy.
The efficacy of Taxol as a radiosensitizer has been evaluated previously (19). Our study
compared the efficacy of Genexol-PM as a radiosensitizer with that of Taxol. At the IC50
dose, Genexol-PM is more effective than Taxol, whereas at the same paclitaxel dose,
Genexol-PM is as effective as Taxol in vitro. The in vitro results reflect the fact that the
advantages of NP therapeutics in chemoradiation therapy are controlled drug release and
biodistribution but only the effects of controlled drug release can be observed in the in vitro
setting. Genexol-PM was also evaluated in vivo as a radiosensitizer in mouse xenograft
models of NSCLC. We demonstrated that at equivalent doses of paclitaxel, Genexol-PM led
to significantly longer tumor growth delay than Taxol in mice treated with chemoradiation
therapy. It is also important to note that we used a relatively low dose of paclitaxel in this
study. This is shown by the lack of tumor growth delay in mice treated with only Taxol or
Genexol-PM compared with mice that received no treatment. Our findings confirm that
Genexol-PM is an effective radiosensitizer. On the basis of NP biodistribution properties,
we also hypothesized that Genexol-PM would lead to lower paclitaxel dose to lungs when
compared with Taxol. Indeed, paclitaxel dose in mouse lungs was significantly lower in
mice given Genexol-PM than that in mice given Taxol at 6 hours after chemotherapy
administration. Because pulmonary toxicity from chemoradiation therapy is related to
paclitaxel dose in normal lung tissue (20), such reduction in paclitaxel dose can result in
lower pulmonary toxicity.
In summary, we have demonstrated that Genexol-PM holds high potential as a
radiosensitizer in chemoradiation therapy for NSCLC. Our findings provide the preclinical
evidence to support the clinical evaluation of Genexol-PM as part of the chemoradiation
therapy regimen for NSCLC. Genexol-PM can be incorporated into existing chemoradiation
therapy regimens in place of Taxol. Results from this study suggest that substituting Taxol
with Genexol-PM can improve the therapeutic ratio of treatment. More broadly, our report
and previously reported preclinical studies suggest that NP chemotherapeutics are more
effective than their small-molecule counterparts as radio-sensitizers. Therefore, the clinical
development of novel NP chemotherapeutics should include clinical evaluations in
chemoradiation therapy. Lastly, given the importance of the chemoradiation therapy
treatment paradigm, nanomedicine research efforts should focus on the development of
novel NP therapeutics with the primary application of improving chemoradiation therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Characterization of Genexol-PM. (A) Transmission electron microscopy image of Genexol-
PM depicting a monodisperse population of particles with a narrow size distribution of 23.0
± 4.5. (B) Drug-release curve of Genexol-PM. Genexol-PM releases paclitaxel (Ptxl) in a
first-order release kinetic. Genexol-PM was incubated in phosphate buffered saline at 37°C.
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Efficacy of Genexol-PM as a radiosensitizer in non-small cell lung cancer cell lines in vitro.
Radiation survival curves for (A) H460 and (B) A549 non-small cell lung cancer cells
treated with saline, Taxol, or Genexol-PM. Cells were irradiated with 2 fractions of
indicated doses 12 hours apart. Significant differences between Taxol and Genexol-PM at a
given dose are indicated (P<.01, †P<.05). Error bars correspond to standard error of the
mean (3 samples per time point). XRT = radiation therapy.
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Efficacy of Genexol-PM as a radiosensitizer in chemoradiation therapy for non-small cell
lung cancer cell cell lines in vivo. Mice bearing flank tumor xenografts were administered
(via tail-vein intravenous injection) saline, Taxol, or Genexol-PM followed by radiation
therapy (XRT). Tumors were irradiated in 5 daily fractions of 3 Gy beginning at 6 hours
after chemotherapy injection. Changes in tumor volume were measured and the tumor
growth delay curves for mice bearing (A) H460 and (B) A549 tumors were generated.
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Quantification of paclitaxel dose in mouse lungs after Genexol-PM administration. Mice
were administered equivalent paclitaxel doses of Taxol and Genexol-PM intravenously.
Lungs were harvested at either 6 or 24 hours posttreatment, and paclitaxel dose was
quantified using liquid chromatography-mass spectrometry.
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